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Background: Polymorphisms in CYP2C19 are related to the metabolic oxidation of drugs to varying degrees. The
CYP3A4*18, CYP3A5*3, and MDR1-3435 variant alleles are very important, particularly in tacrolimus metabolism in
organ transplant rejection.
Aim: The aim of this study is o explore possible interactions among different CYP2C19 genotypes, namely, between
homozygous extensive metabolizers (HomEM), heterozygous extensive metabolizers (HetEM), and poor
metabolizers (PM), and the CYP3A4*18, CYP3A5*3, and MDR1-3435 variants in living donors and patients who
received a living donor liver transplant (LDLT).
Methods: This prospective study enrolled 133 living donors and 133 corresponding recipients. On the basis of the
HomEM, HetEM, and PM CYP2C19 genotypes, the distributions of CYP3A4*18 (exon 10; T878C), CYP3A5*3 (intron 3;
A6986G), and MDR1-3435 (exon 26; C3435T) genotypes were analyzed for single nucleotide polymorphisms among
donors and recipients.
Results: Among 102 HomEM genotypes, including 56 donors and 46 recipients, 91.2% of individuals harbored the
T/T genotype of CYP3A4*18; 53.9% possessed G/G, and 34.3% had A/G genotypes of CYP3A5*3; and 38.2% had C/C
and 50.0% had C/T genotypes at MDR1-3435. Among 130 HetEM genotypes, including 58 donors and 72 recipients,
97.7% of individuals possessed T/T genotype at CYP3A4*18; 50.0% harbored G/G and 41.5% had A/G genotypes at
CYP3A5*3; and 40.0% had C/C and 49.2% had C/T genotypes at MDR1-3435. In 34 PMs, including 19 donors and 15
recipients, 88.2% had T/T genotypes at CYP3A4*18; 41.2% had G/G and 58.8% had A/G genotypes at CYP3A5*3; and
47.1% possessed C/C and 47.1% had C/T genotypes at MDR1-3435. On the basis of the CYP2C19 genotypes, no
statistically significant distribution of genotypes were observed between donors and recipients for all genotypes of
CYP3A4*18, CYP3A5*3, and MDR1-3435 (P >0.05).
Conclusions: In conclusion, the CYP2C19 genotypes do not affect the expression of CYP3A4*18, CYP3A5*3, or MDR1-
3435 variants, which are independently distributed among donors and recipients during LDLT.
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Cytochrome P450 in the liver is one of the key enzyme
complexes in the primary drug-metabolizing system in
humans. Recipients of living-donor liver transplantation
(LDLT) exhibit interesting biological distributions of
CYP2C19 genotypes that differ between the recipient’s
tissue and the newly grafted tissue [1]. Acute rejection
or abnormal postoperative liver function after LDLT
could result from complications in cytochrome P450
function [2,3]. We have recently reported a homogenous
phenomenon observed in CYP2C19 genotypes [4]. Anti-
rejection agents such as tacrolimus usually target CYP3A4,
CYP3A5, and MDR-1, which are the major metabolic iso-
enzymes of cytochrome P450. In the present study, we
aimed to investigate the CYP2C19 genotypes, which have
been classified as homozygous extensive metabolizers
(HomEM), heterozygous extensive metabolizers (HetEM),
and poor metabolizers (PM), and to identify any interac-
tions between the CYP3A4*18, CYP3A5*3, and MDR1-
3435 variants by characterizing differences between the
genotype distribution of healthy living donors and patients
with liver disease who received LDLT.
Methods
This present study included 133 living donors and 133
consecutive LDLT recipients who were enrolled in our
transplantation program. The mean age of the recipients
was 42.62 years (range, 0.6 to 68 years), including 98
male and 35 female subjects. The etiologies for LDLT
are shown in Table 1. There were 60 (45.1%) recipients
with hepatitis B-related end-stage liver disease (ESLD),
of which 35 (58.3%) were associated with hepatocellular
carcinoma (HCC); 22 (16.5%) recipients with hepatitis
C-related ESLD, including 11 (50.0%) with HCC; 9 (6.8%)
recipients with both hepatitis B- and C-related ESLD, in-
cluding 5 (55.6%) with HCC; 8 (6.0%) recipients with
alcoholic-related ESLD, including 2 (25%) with HCC; and
23 pediatric recipients with biliary atresia. The remainingTable 1 Etiology of the 133 study subjects who required
living donor liver transplantation
Category Recipient Associated with HCC
N (%) N (%)
HBV 60 (45.1) 35 (58.3)
HCV 22 (16.5) 11 (50.0)
HBV + HCV 9 (6.8) 5 (55.6)
Alcoholic 8 (6.0) 2 (25.0)
Biliary atresia 23 (17.3)
Othera 11 (8.3)
Total 133 (100) 53 (39.9)
aautoimmune (1), Alagille syndrome (3), portal vein occlusion (1), primary
biliary cirrhosis (2), polycystic liver (1), and cryptogenic liver cirrhosis (3).
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.11 recipients had autoimmune liver disease (1 patient),
Alagille syndrome (3 patients), portal vein occlusion (1
patient), primary biliary cirrhosis (2 patients), polycystic
liver (1 patient), or cryptogenic liver cirrhosis (3 pa-
tient). Complete liver function was assessed on day 1
after liver transplantation (D1) and on day 30 after liver
transplantation (D30), including measurements of ala-
nine transferase (ALT), aspartate transferase (AST),
total bilirubin (T-Bil), prothrombin time (PT) with
international normal range (INR), and albumin (Alb).
Donors and recipients were classified on the basis of the
CYP2C19 genotype, as detailed in our previous report
[1]. HomEMs were individuals with wild-type alleles
(genotype: *1/*1), whereas HetEMs were those who pos-
sessed a single mutated allele (genotype: *1/*2 or *1/*3).
Patients with homozygous mutations (m1 in exon 5 or
m2 in exon 4) of CYP2C19 (genotype: *2/*2, *3/*3, or
*2/*3) were defined as PMs. This study comprised a
total of 102 HomEMs, including 56 donors and 46 re-
cipients; 130 HetEMs, including 58 donors and 72 re-
cipients; and 34 PMs, including 19 donors and 15
recipients. On the basis of the CYP2C19 genotype clas-
sification, HomEM, HetEM, or PM individuals were an-
alyzed to test for carrier status of other known single
nucleotide polymorphism (SNP) variant alleles to deter-
mine biological distributions of CYP3A4*18 (exon 10;
T878C), CYP3A5*3 (intron 3; A6986G), and MDR1-3435
(exon 26; C3435T). Genomic DNA was extracted from
peripheral leukocytes and genotyped for evaluating the
CYP2C19, CYP3A4*18, CYP3A5*3, and MDR1-3435 status
by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) and direct sequencing analysis.
Genotyping of CYP3A4, CYP3A5, and MDR1-3435
Polymerase chain reaction/ligase detection reaction assay
(PCR/LDR) was employed for genotyping the CYP3A4*18B
and CYP3A5*3 SNPs. The PCR conditions consisted of a
denaturation step at 95°C for 15 min, followed by 35 cycles
of 94°C for 30 s, 65°C for 1 min, and 72°C for 1 min,
followed by a final extension step at 72°C for 7 min. The
specific amplified fragments were used in an LDR assay to
identify the mutations associated with CYP3A4*18B and
CYP3A5*3. The LDR assay was performed as follows: 10
μL of the reaction mix contained 1 μL of 1× ligase reaction
buffer (New England Biolabs, USA), 1 μL of probes (12.5
pmol/μL each), 0.05 μL (2 U) of thermostable Taq DNA
ligase (New England Biolabs), and 1 μL of PCR product.
The ligation reaction was performed with a GeneAmp
PCR System 9600 (Perkin Elmer, USA) as follows: 15 min
at 95°C, followed by 35 cycles of 30 s at 94°C and 2 min
at 60°C. The products were separated by agarose gel
electrophoresis and analyzed with an ABI PRISM 377
DNA sequencer [5]. Genotyping was performed using
an independent external contractor (Biowing Applied
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lated from whole blood using the UltraPure™ Genomic
DNA Isolation Kit (Shanghai SBS Genetech Technology
Co., China). PCR-RFLP was performed to genotype exon
26 (C3435T) variant alleles in the MDR1 gene, with slight
modifications. The PCR conditions consisted of a denatur-
ation step at 95°C for 5 min, followed by 30 cycles of de-
naturation at 94°C for 30 s, annealing at 54°C to 59°C for
50 s, and elongation at 72°C for 1 min, followed by a final
extension at 72°C for 10 min. PCR products were digested
with DpnII (C3435T) and analyzed by electrophoretic sep-
aration on agarose gels, followed by direct visualization
over an ultraviolet transilluminator after ethidium brom-
ide staining [6].
This work was supported by a grant from Chang Gung
Memorial Hospital (CMRPG8A0631 to K-WC) of Taiwan,
which also granted ethical approval to our study. This
study was approved by the Institutional Review Board
(IRB), and informed consent was obtained from partici-
pants or from a parent or guardian in case of minor
participants.
Statistical analyses
Statistical analyses were performed using SPSS software
(version 12.0; SPSS, Chicago, IL, USA). Parameters be-
tween HomEM or HetEM and PMs in donors and recip-
ients were compared using the X2 test, Fisher’s exact
test, and Student’s t-test. P values less than 0.05 were
considered statistically significant.
Results
In this study, 68.4% (91/133) of ESLD cases were virus-
related, including 45.1% (60/133) of hepatitis B cases,
16.5% (22/133) of hepatitis C cases, and 6.8% (9/133) of
cases with both hepatitis B and C. Furthermore, 39.9%
(53/133) recipients had HCC. Excluding the 23 biliary
atresia and 3 Alagille syndrome pediatric cases, 49.5%Table 2 Clinical profiles of 133 donors and 133 recipients for
their clinical profiles on day 1 (D1) and day 30 (D30) after tra
Category Donor N = 133 Recipient
Age (mean) (range) 30.27 (18 to 53) 42.62 (0
Sex M:F 83:50 98:
D1
ALT 14.43 ± 14.75 252.35 ± 446.40
AST 18.3 ± 7.19 292.42 ± 660.86
T-Bil 0.64 ± 0.57 7.19 ± 11.71
PT (INR) 0.97 ± 0.09 1.91 ± 3.34
Alb 4.24 ± 0.79 3.06 ± 0.88
Tacrolimus (ng/mL) (n = 107) 2.51 ± 2.73
cyA (ng/mL) (n = 26) 283.89 ± 308.93
D, donor; D1, post liver transplantation day 1; D30, post liver transplantation day 30(53/107) of adult recipients had HCC (Table 1). Clinical
profiles of the 133 donors and 133 recipients on the day
of the LDLT operation are shown in Table 2. The mean
age of the donor population was significantly younger
than the recipient population (30.27 years (range 18 to 53
years) versus 42.62 years (range 0.6 to 68 years); P <0.001).
On D1 of liver transplantation, all donors showed signifi-
cantly better results of all liver function tests than did the
recipients, including ALT (14.43 ± 14.75 versus 252.35 ±
446.40; P <0.001), AST (18.3 ± 7.19 versus 292.42 ± 660.86;
P <0.001), T-Bil (0.64 ± 0.57 versus 7.19 ± 11.71; P <0.001),
PT (INR) (0.97 ± 0.09 versus 1.91 ± 3.34; P = 0.003), and
Alb (4.24 ± 0.79 versus 3.06 ± 0.88; P <0.001). On D30,
after LDLT, all liver function tests of the recipients were sig-
nificantly better than those on D1, including ALT (252.43 ±
446.40 versus 82.40 ± 244.43, P <0.001), AST (292.42 ±
660.86 versus 65.54 ± 300.20, P <0.001), T-Bil (7.19 ± 11.71
versus 1.24 ± 3.60, P <0.001), PT (INR) (1.91 ± 3.34 versus
1.05 ± 0.40, P <0.001), and Alb (3.06 ± 0.88 versus 3.74 ±
0.95, P <0.001).
On the day of LDLT, 107 adult recipients received ta-
crolimus and 26 pediatric recipients received cyclospor-
ine A (CsA). The serum concentrations of tacrolimus
and CsA were 2.51 ± 2.73 ng/mL and 283.89 ± 308.93
ng/mL, respectively, on D1 and 6.17 ± 9.58 ng/mL and
1058.30 ± 582.37 ng/mL, respectively, on D30; these re-
sults show that the serum concentrations of both tacroli-
mus and cyA were significantly higher on D30 than on
D1 after LDLT (P <0.001; Table 2).
Among the 266 subjects with CYP2C19 genotypes
(comprising 133 healthy donors and 133 diseased recipi-
ents), 102 had HomEM genotypes, including 56 donors
and 46 recipients. The 2 wild-type CYP3A4*18 geno-
types, T/T and T/C genotypes, were distributed as fol-
lows: 53.8% (50/93) of individuals with the T/T genotype
were donors and 46.2% (43/93) were recipients, and
66.7% (6/9) of cases with the T/C genotype were donorsliving donor liver transplantation and comparison of
nsplantation
N = 133 P value
.6-68) <0.001
35 0.292
D30 D:RD1 D:RD30 RD1:RD30
82.40 ± 244.43 <0.001 0.003 <0.001
65.54 ± 300.20 <0.001 0.087 <0.001
1.24 ± 3.60 <0.001 0.071 <0.001
1.05 ± 0.40 0.003 0.025 <0.001
3.74 ± 0.95 <0.001 0.148 <0.001
6.17 ± 9.58 <0.001
1058.30 ± 582.37 <0.001
; R, recipient.
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types namely, G/G, A/G, and A/A were distributed as
follows: 58% (32/55) of individuals with the G/G geno-
type were donors and 42.0% (23/55) were recipients,
48.6% (17/35) of individuals with the A/G genotype were
donors and 51.4% (18/35) were recipients, and 58.3% (7/
12) of individuals with the A/A genotype were donors
and 41.7% (5/12) were recipients. The 3 MDR1-3435 ge-
notypes, C/C, C/T, and T/T, were distributed as follows:
59.0% (23/39) of individuals with the C/C genotype were
donors and 41.0% (16/39) were recipients, 56.9% (29/51)
of individuals with the C/T genotype were donors and
43.1% (22/51) were recipients, and 33.3% (4/12) of indi-
viduals with the T/T genotype were donors and 66.7%
(8/12) were recipients. There was no statistically signifi-
cant correlation between healthy donors and diseased
recipients bearing the CYP2C19 HomEM genotype with
CYP3A4*18, CYP3A5*3, or MDR1-3435 polymorphisms
(P >0.05).
In this study, 130 individuals had the HetEM genotype,
including 58 donors and 72 recipients. The 2 wild-type
and CYP3A4*18 genotypes were distributed as follows:
45.7% (58/127) of individuals with the T/T genotype
were donors and 54.3% (69/93) were recipients, and 0%
(0/3) of those with the T/C genotype were donors and
100.0% (3/3) were recipients. The 3 CYP3A5*3 geno-
types were distributed as follows: 46.2% (30/65) of indi-
viduals with the G/G genotype were donors and 53.8%
(35/65) were recipients, 48.0% (26/54) of individuals
with the A/G genotype were donors and 52.0% (28/54)
were recipients, and 18.2% (2/11) of individuals with the
A/A genotype were donors and 81.8% (9/11) wereTable 3 Association between the CYP2C19 genotypes: CYP3A4
recipients after living donor liver transplantation
CYP2C19 CYP3A4*18a
Genotype (n) T/T T/C G/G
HomEM: n = 102 (%) 93 (91.2) 9 (8.8) 55 (53.9)
D: n = 56 (%) 50 (53.8) 6 (66.7) 32 (58)
R: n = 46 (%) 43 (46.2) 3 (33.3) 23 (42)
HetEM: n = 130 (%) 127 (97.7)d 3 (2.3)d# 65 (50.0)
D: n = 58 (%) 58 (45.7) 0 (0) 30 (46.2)
R: n = 72 (%) 69 (54.3) 3 (100) 35 (53.8)
PM: n = 34 (%) 30 (88.2)d 4 (11.8)d 14 (41.2)
D: n = 19 (%) 16 (53.3) 3 (75) 9 (64.3)
R: n = 15 (%) 14 (46.7) 1 (25) 5 (35.7)
D, donor; HetEM, heterozygous extensive metabolizers; HomEM, homozygous exten
10; T878C).
bCYP3A5*3 (intron 3; A6986G).
cMDR1-3435 (exon 26; C3435T).
dP < 0.05. There was no statistically significant difference between the haplotypes o
C/T, and T/T) and also between the different CYP2C19 genotypes (HomEM, HetEM, a
There were independent isoenzymes and no correlation of genetic interaction betw
variant haplotypes or genotypes.recipients. The 3 MDR1-3435 genotypes were distrib-
uted as follows: 42.3% (22/52) of individuals with the C/
C genotype were donors and 57.7% (30/52) were recipi-
ents, 50.0% (32/64) of individuals with the C/T genotype
were donors and 50.0% (32/64) were recipients, and
28.6% (4/14) of individuals with the T/T genotype were
donors and 71.4% (10/14) were recipients. No statistically
significant association was observed between healthy do-
nors and diseased recipients with the CYP2C19 HetEM
genotype and the CYP3A4*18, CYP3A5*3, or MDR1-3435
genotypes (P >0.05). The data presented in Table 3 sum-
marizes the negative correlations between the HomEM,
HetEM, and PM CYP2C19 genotypes and the CYP3A4*18,
CYP3A5*3, or MDR1-3435 genotypes. Our data indicate
that these genotypes had similar distributions in both do-
nors and recipients, suggesting that there were no statisti-
cally significant differences between CYP3A4*18 (T/T and
T/C), CYP3A5*3 (G/G, A/G and A/A), and MDR1-3435
(C/C, C/T and T/T) haplotypes, as well as the different
CYP2C19 HomEM, HetEM, and PM genotypes between
healthy donors and recipients with ESLD. Hence, there
were independent isoenzymes and no correlation of gen-
etic interaction between CYP2C19 and CYP3A4*18,
CYP3A5*3, or MDR1-3435 not only, but also the variant
haplotypes or genotypes.
There were 34 PMs in this cohort, including 19 donors
and 15 recipients. The 2 wild-type CYP3A4*18 geno-
types were distributed as follows: 3.3% (16/30) of indi-
viduals with the T/T genotype were donors and 46.7%
(14/30) were recipients, 75.0% (3/4) of individuals with
the T/C genotype were donors and 25.0% (1/4) were re-
cipients. Only 2 of the possible CYP3A5*3 genotypes were*18, CYP3A5*3, and MDR1-3435 in 133 donors and 133
CYP3A5*3b MDR1-3435c
A/G A/A C/C C/T T/T
35 (34.3) 12 (11.8) 39 (38.2) 51 (50.0) 12 (11.8)
17 (48.6) 7 (58.3) 23 (59) 29 (56.9) 4 (33.3)
18 (51.4) 5 (41.7) 16 (41) 22 (43.1) 8 (66.7)
54 (41.5) 11 (8.5) 52 (40) 64 (49.2) 14 (10.8)
26 (48) 2 (18.2) 22 (42.3) 32 (50) 4 (28.6)
28 (52) 9 (81.8) 30 (57.7) 32 (50) 10 (71.4)
20 (58.8) 16 (47.1) 16 (47.1) 2 (5.9)
10 (50) 0 11 (68.8) 6 (37.5) 2 (100)
10 (50) 5 (31.2) 10 (62.5) 0 (0)
sive metabolizers; PM, poor metabolizers; R: recipient.; aCYP3A4*18 (exon
f CYP3A4*18 (T/T and T/C), CYP3A5*3 (G/G, A/G, and A/A), and MDR1-3435 (C/C,
nd PM) between healthy donors and recipients with end stage liver disease.
een CYP2C19 and CYP3A4*18, CYP3A5*3, or MDR1-3435 not only, but also the
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dividuals with the G/G genotype were donors and 35.7%
(5/14) were recipients, and 50.0% (10/20) of individuals
with the A/G genotype were donors and 50.0% (10/20)
were recipients. No CYP3A5*3 A/A genotypes were
detected. The 3 MDR1-3435 genotypes were distributed
as follows: 68.8% (11/16) of individuals with the C/C
genotype were donors and 31.2% (5/16) were recipients,
37.5% (6/16) of individuals with the C/T genotype were
donors and 62.5% (10/16) were recipients, and 100.0%
(2/2) of individuals with the T/T genotype were donors.
No statistically significant association was found be-
tween healthy donors and diseased recipients either with
the CYP2C19 PM genotype or with the CYP3A4*18,
CYP3A5*3, and MDR1-3435 genotypes (P >0.05).
Discussion
From our previous studies, we know that CYP2C19 ex-
presses three genotypes with different drug metabolization
capacities [1,3]. In this study, we attempted to investigate
possible genetic interactions between CYP2C19 and
CYP3A4*18, CYP3A5*3, or MDR1-3435 in detail. In the
present study, we focused on the expression of genetic
polymorphisms in the CYP3A4*18, CYP3A5*3, and
MDR1-3435 genotypes. No significant differences were
found in the distributions between CYP3A4*18 (exon
10; T878C), CYP3A5*3 (intron 3; A6986G), or MDR1-
3435 (exon 26; C3435T) genotypes on the basis of dif-
ferent CYP2C19 genotypes between healthy liver donors
and patients with poor liver function who received LDLT.
Although all these proteins are important isoenzymes of
cytochrome P450 in drug metabolism in the liver, only the
differences in CYP2C19 genotypes have been documented
[1]. CYP3A4*18, CYP3A5*3, and MDR1-3435 polymor-
phisms do not appear to have a functional effect following
LDLT in either the donor with normal liver function orFigure 1 Flow chart of the possible relationship between CYP2C19 genothe recipient with ESLD. A recent study showed that the
CYP2C19 genotype, unlike MDR1 and IL-1B genotypes,
had an impact on the efficacy of Helicobacter pylori eradi-
cation in peptic ulcer patients treated with pantoprazole
in triple therapy administrations [7]. In the present study,
individuals receiving LDLT who had different CYP2C19
genotypes (HomEM [41 and 43.1%], HetEM [57.7 and
50%], and PM [31.2 and 62.5%]) did not show different
distributions of CYP3A4*18, CYP3A5*3, and MDR1-3435
genotypes (C/C and C/T). This observation was consistent
in both donors and recipients.
After LDLT, the serum levels of immunosuppressive
agents were significantly lower on D1 than on D30,
whereas the results of all liver functional tests (ALT,
AST, T-Bil, PT(INR), and Alb) were significantly higher
on D1 than on D30. These results led us to hypothesize
that the immunosuppressive agents affected the stability
of metabolic enzymes in the cytochrome P450 system.
Previous published reports describe CYP3A as the most
abundant enzyme of the P450 subfamily in the human
liver and intestine, accounting for 30% of the total P450
in the human liver, and metabolizing approximately 50%
of currently used clinical drugs [8-10]. The impacts of
different CYP2C19, CYP3A4*18, CYP3A5*3, and MDR1-
3435 genotypes on LDLT have been outlined in a flow
chart presented in Figure 1. In our previous study, the
homogenous phenomenon was attributed to the different
CYP2C19 genotypes (HomEM, HetEM, and PM) between
an LDLT donor and recipient owing to the uniqueness of
the human liver [4]. The metabolism of the proton pump
inhibitor (PPI) was dependent on the CYP2C19 genotypes
in the cytochrome P450 system, primarily in the liver.
HomEM genotypes were found to better metabolize some
drugs than did the HetEM and PM genotypes during
LDLT [1]. If the donor possessed a CYP2C19 PM geno-
type, the recipient assumed a PM genotype (rather thantypes and CYP3A4*18, CYP3A5*3, and MDR1-3435 genotypes. [4].
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homogenous phenomenon [4]. In contrast, the CYP3A4*18
and CYP3A5*3 genetic polymorphisms have two origins:
the liver and intestine [8,9]. In the postnatal human liver,
CYP3A4 and CYP3A5 are the two major CYP3A enzymes,
which have overlapping substrate specificities [10]. When
the liver function worsens, the drug metabolic function of
the intestine may compensate, leading to unaltered drug
metabolism, such as for tacrolimus (Figure 1). Depending
on the liver function, the CYP2C19 genotypes HomEM,
HetEM, and PM were more likely to present abnormal
postoperative liver function and graft pathology [3]; how-
ever, this was not observed in the present study for the
CYP3A4*18, CYP3A5*3, and MDR1-3435 polymorphisms
in LDLT. As reported previously, CYP2C19 genotype ex-
pression is not demonstrated well by western blotting [11].
CYP3A5 protein expression is highly variable in the human
liver, in particular, because of the high frequency of a SNP
CYP3A5*3 A6986G in an intron [12]. The CYP3A4*18B
SNP in intron 10 was first discovered by direct sequencing
in a Japanese population. It was speculated that this variant
was associated with increased CYP3A4 activity [5], and this
speculation was extended by exploring cyclosporin A
(CsA) metabolism in healthy Chinese subjects [6]. A num-
ber of SNPs have been identified in the MDR1 gene by
large-scale sequencing. For example, our study probed the
C3435T variant in exon 26 [13,14]. The PCR-RFLP method
to detect the MDR1 3435C/T polymorphism has also been
widely used, as was used recently in our study [7]. Al-
though there is no evidence suggesting that intestinal
expression of CYP3A4, CYP3A5, and MDR-1 play an im-
portant role, human cytochrome P450 enzymes have
been expressed in Escherichia coli. Simplified bacterial
systems can explain the possibility of intestinal activa-
tion of these enzymes [15]. A previous study has shown
that the intestinal mucosa contains prominent forms of
cytochrome P450, which are similar to liver cytochrome
P450p in their structure, function, and some regulatory
characteristics [16].
Therefore, the results of the present study do not
impel us to change strategies and to combine certain do-
nors with certain recipients. According to our previous
study, evidence for graft rejection occurred within a
month after LDLT [2]. In other words, the cytochrome
P450 system stabilizes with time, up to 1 month after
LDLT. The increase in serum level of immunosuppres-
sive agents is followed by clinical liver functions leading
to stability. Whether these studies can be performed in
cadaveric liver transplantation cases is presently unclear.
In our cohort, 68.4% of individuals receiving LDLT
had underlying chronic viral hepatitis-related ESLD,
including 39.9% of individuals who had HCC. There was
no difference in CYP3A4*18, CYP3A5*3, and MDR1-
3435 genotypes between the donors and recipients. Inaddition to the etiology of the underlying disease, age
also did not influence the distribution of CYP3A4*18,
CYP3A5*3, and MDR1-3435 genotypes. No remarkable
difference was observed between donors and recipients,
as well as between pediatric and adult recipients.
From our data, the haplotypes of the CYP3A4*18,
CYP3A5*3 or MDR1-3435 do not seem to correlate with
tacrolimus metabolism in these recipients, but the vari-
ant stability of these enzymes are significantly different
on D1 and D30 after LDLT. Drug levels were lower on
D1 and higher on D30, but there were no correlations to
the haplotypes of CYP3A4*18, CYP3A5*3, or MDR1-
3435 and/or different genotypes of CYP2C19 HomEM,
HetEM, and PM, except for their stability.
In conclusion, the CYP2C19 genotypes, HomEM,
HetEM, and PM, do not affect the expression of
CYP3A4*18, CYP3A5*3, and MDR1-3435 polymor-
phisms. These polymorphisms were independently dis-
tributed among donors and recipients, as well as healthy
and diseased livers, because the source may be located
outside the liver during LDLT.
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